The global injection pen market size is calculated at USD 43.03 billion in 2025 and is forecasted to reach around USD 79.78 billion by 2034, accelerating at a CAGR of 7.10% from 2025 to 2034. The North America injection pen market size surpassed USD 17.28 billion in 2024 and is expanding at a CAGR of 7.22% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Injection Pen Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Injection Pen Market, by Product Type
8.1.1. Reusable
8.1.1.1. Market Revenue and Forecast
8.1.2. Disposable
8.1.2.1. Market Revenue and Forecast
9.1. Injection Pen Market, by End User
9.1.1. Hospitals & Diagnostic Centers
9.1.1.1. Market Revenue and Forecast
9.1.2. Homecare
9.1.2.1. Market Revenue and Forecast
10.1. Injection Pen Market, by Therapy
10.1.1. Diabetes
10.1.1.1. Market Revenue and Forecast
10.1.2. Cancer
10.1.2.1. Market Revenue and Forecast
10.1.3. Osteoporosis
10.1.3.1. Market Revenue and Forecast
10.1.4. Autoimmune Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Growth Hormone Therapy
10.1.5.1. Market Revenue and Forecast
10.1.6. Multiple Sclerosis
10.1.6.1. Market Revenue and Forecast
10.1.7. Others
10.1.7.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product
11.1.2. Market Revenue and Forecast, by End User
11.1.3. Market Revenue and Forecast, by Therapy
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by End User
11.1.4.3. Market Revenue and Forecast, by Therapy
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product
11.1.5.2. Market Revenue and Forecast, by End User
11.1.5.3. Market Revenue and Forecast, by Therapy
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product
11.2.2. Market Revenue and Forecast, by End User
11.2.3. Market Revenue and Forecast, by Therapy
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product
11.2.4.2. Market Revenue and Forecast, by End User
11.2.4.3. Market Revenue and Forecast, by Therapy
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product
11.2.5.2. Market Revenue and Forecast, by End User
11.2.5.3. Market Revenue and Forecast, by Therapy
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product
11.2.6.2. Market Revenue and Forecast, by End User
11.2.6.3. Market Revenue and Forecast, by Therapy
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product
11.2.7.2. Market Revenue and Forecast, by End User
11.2.7.3. Market Revenue and Forecast, by Therapy
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product
11.3.2. Market Revenue and Forecast, by End User
11.3.3. Market Revenue and Forecast, by Therapy
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product
11.3.4.2. Market Revenue and Forecast, by End User
11.3.4.3. Market Revenue and Forecast, by Therapy
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product
11.3.5.2. Market Revenue and Forecast, by End User
11.3.5.3. Market Revenue and Forecast, by Therapy
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product
11.3.6.2. Market Revenue and Forecast, by End User
11.3.6.3. Market Revenue and Forecast, by Therapy
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product
11.3.7.2. Market Revenue and Forecast, by End User
11.3.7.3. Market Revenue and Forecast, by Therapy
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product
11.4.2. Market Revenue and Forecast, by End User
11.4.3. Market Revenue and Forecast, by Therapy
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product
11.4.4.2. Market Revenue and Forecast, by End User
11.4.4.3. Market Revenue and Forecast, by Therapy
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product
11.4.5.2. Market Revenue and Forecast, by End User
11.4.5.3. Market Revenue and Forecast, by Therapy
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product
11.4.6.2. Market Revenue and Forecast, by End User
11.4.6.3. Market Revenue and Forecast, by Therapy
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product
11.4.7.2. Market Revenue and Forecast, by End User
11.4.7.3. Market Revenue and Forecast, by Therapy
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product
11.5.2. Market Revenue and Forecast, by End User
11.5.3. Market Revenue and Forecast, by Therapy
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product
11.5.4.2. Market Revenue and Forecast, by End User
11.5.4.3. Market Revenue and Forecast, by Therapy
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product
11.5.5.2. Market Revenue and Forecast, by End User
11.5.5.3. Market Revenue and Forecast, by Therapy
12.1. Eli Lilly
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novo Nordisk
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sanofi
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Ypsomed
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F.Hoffman-La Roche
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Becton Dickinson and Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novartis
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Haselmeier
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Owen Mumford
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. WOCKHARDT
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample